Skip to main content
Caplight Logo









RiboPro

RiboPro

Private
OssHealthcare & Life Scienceshttps://ribopro.eu/

Last Round

Series A

Oct 31, 2024

Total Funding Raised

$7.56M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

RiboPro is a biotechnology company that provides messenger RNA (mRNA) and lipid nanoparticle (LNP) development and manufacturing services.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

contract development and manufacturing organizationmessenger RNAmRNACDMOLNPlipid nanoparticlemRNA manufacturingGMP manufacturingLNP formulationmRNA synthesisCROmRNA therapeuticsmRNA vaccinescontract research organizationsequence designsaRNAcircRNAtechnology licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

RiboPro Comparables

Compare RiboPro with similar companies based on industry and business-model similarity.

RiboPro comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ARCALIS, Inc.
83%
Maravai Lifesciences Holdings, Inc.
74%
Danaher Corporation
69%

RiboPro Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 31, 2024
Convertible DebtJan 10, 2024
GrantOct 27, 2021
SeedMar 22, 2021

Key People

Founding team and executive leadership

Sigi Neerken

Chief Operating Officer

Executive Team

Silvy Van Tuijl

COS, COO

Executive Team

RiboPro Investors

Notable investors and investment history

RiboPro investors
InvestorRounds
Mountainview Capital PartnersSeries A
RockstartSeed, Series A
Brabantse Ontwikkelings MaatschappijConvertible Debt, Seed
CEPIGrant
Wellcome LeapGrant
BOM Brabant VenturesSeries A
Vlasroot GroupConvertible Debt, Series A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 29, 2026

    Grew 16% QoQ, from 37 to 43 employees.

  • Jun 19, 2026

    Monthly visitors increased 43% MoM, reaching 1.6K.

RiboPro Filings

Explore SEC and related filing metadata, where available.

RiboPro filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about RiboPro's valuation, stock price, and market status.

Is RiboPro a public or private company?

RiboPro is a private company.

What is the current stock price of RiboPro?

RiboPro is a private company with no public stock price. No recent secondary market data is available.

How much is RiboPro worth (valuation)?

Valuation information for RiboPro is not publicly available.

Can I buy RiboPro stock?

RiboPro shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was RiboPro's last funding round?

RiboPro's most recent funding round was Series A on October 31, 2024.

Who are the main investors in RiboPro?

Key investors in RiboPro include Wellcome Leap, Vlasroot Group.

Will RiboPro IPO soon?

No public IPO plans have been announced for RiboPro.

How can I track RiboPro secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor RiboPro's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersOss
Employee Range32
Year Founded2020
Last FundingOct 31, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?